Ophthalmology Department, Complejo Hospitalario Universitario de León, León, Spain.
Ocul Immunol Inflamm. 2013 Jun;21(3):212-9. doi: 10.3109/09273948.2013.770888. Epub 2013 Apr 25.
To report the effect of adalimumab on serum cytokines in chronic refractory uveitis.
Prospective study on the effects of adalimumab on serum cytokine levels at different time points in a cohort of 12 refractory chronic uveitis patients. Results were analyzed according to clinical outcomes and compared with systemic steroid-treated recurrent uveitis patients.
Before treatment, patients exhibited significantly increased IL-1β, IL-6, TNFα, IL-12 p70, IL-10, and IL-22. Adalimumab significantly decreased IL-6, and IL-12p70 at early time points (after 1 month of treatment). Adalimumab effects on IL-10 and IL-22 appeared later (after 6 months of treatment). IL-1β, IL-17A, and TNFα were not modified at any time point. Only decreased IL-22 serum levels correlated with disease activity (p = 0.011). These effects were not observed in steroid-treated patients.
Adalimumab induced drug-specific and time-dependent declines in serum levels of particular cytokines, although only IL-22 correlated with disease activity in 10 out 12 patients.
报告阿达木单抗对慢性难治性葡萄膜炎患者血清细胞因子的影响。
对 12 例难治性慢性葡萄膜炎患者在不同时间点接受阿达木单抗治疗的血清细胞因子水平的影响进行前瞻性研究。根据临床结果进行分析，并与接受全身皮质类固醇治疗的复发性葡萄膜炎患者进行比较。
治疗前，患者的 IL-1β、IL-6、TNFα、IL-12p70、IL-10 和 IL-22 水平显著升高。阿达木单抗在早期（治疗 1 个月后）显著降低了 IL-6 和 IL-12p70。阿达木单抗对 IL-10 和 IL-22 的作用在 6 个月后才显现出来。在任何时间点，IL-1β、IL-17A 和 TNFα均未发生变化。只有降低的 IL-22 血清水平与疾病活动度相关（p=0.011）。这些作用在接受皮质类固醇治疗的患者中未观察到。
阿达木单抗诱导了特定细胞因子的药物特异性和时间依赖性下降，但在 12 例患者中的 10 例中，只有 IL-22 与疾病活动度相关。
